AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03117166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
Trial: NCT01605344
Drug: FOLFIRI.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive FOLFIRI infusion on day 1 and day 15.
Trial: NCT03031691
Drug: trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03320070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for SC injection
Trial: NCT02041195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00621452
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01728753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
Trial: NCT04543123
Drug: Antidepressant Drug(escitalopram)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
Trial: NCT00286130
Drug: FOLFOX 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:
Trial: NCT00286130
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Trial: NCT01461668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two times a day for 5 days
Trial: NCT01880424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching Placebo Capsules, Oral, once daily
Trial: NCT00650091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo each day.
Trial: NCT00502320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet at bedtime for up to 4 months
Trial: NCT03558555
Drug: Acetaminophen IV Soln
RxNorm normalized name: acetaminophen Oral Solution
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg of IV acetaminophen
Trial: NCT03558555
Drug: Oral Acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral acetaminophen 975mg pills
Trial: NCT03558555
Drug: Placebo Pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo match to acetaminophen
Trial: NCT04096326
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-151586 solution for injection.
Trial: NCT04096326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for injection.
Trial: NCT04390737
Drug: HH2853 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
Trial: NCT03624101
Drug: symdeko/Trikafta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR modulator
Trial: NCT01106625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Trial: NCT01106625
Drug: Sulphonylruea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Trial: NCT02652312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
Trial: NCT00555048
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00555048
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00907153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth once daily for 12 weeks
Trial: NCT01275625
Drug: HIV therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
Trial: NCT01244347
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03119454
Drug: Diprospan
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular
Trial: NCT00642746
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
Trial: NCT00642746
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
Trial: NCT01040208
Drug: placebo 2 tablets qhs
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg placebo
Trial: NCT01634321
Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral suspension given once
Trial: NCT00871949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to match oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed conditions, 600 mg oral suspension given once
Trial: NCT00871949
Drug: PNU-100480
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral suspension given once
Trial: NCT00005612
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04662242
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 100ml iv infusion for 7 days
Trial: NCT00382980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
Trial: NCT04536337
Drug: ALG-000184
RxNorm normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of ALG-000184
Trial: NCT04536337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple doses of Placebo
Trial: NCT03887858
Drug: Harnal-D Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harnal-D Tab. 1T single oral administration under fasting
Trial: NCT00375518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
Trial: NCT01553643
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at a rate of 3g two times per day
Trial: NCT00535015
Drug: Betamarc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tabs BID
Trial: NCT00717262
Drug: HQK-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
Trial: NCT00717262
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered once a day, orally, for 14 days.
Trial: NCT03212456
Drug: opioid-free group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
Trial: NCT03212456
Drug: Opioid Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will receive fentanyl in the induction of anesthesia.
Trial: NCT00826670
Drug: Placebo (Decolonization)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00000457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
Trial: NCT03430817
Drug: Citicholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
Trial: NCT04118114
Drug: PRL3-zumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration every 2 weeks
Trial: NCT00972829
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10 or 20 milligrams once or twice a week
Trial: NCT00054249
Drug: T900607
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00620113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
Trial: NCT02973516
Drug: P03277 at 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
Trial: NCT02973516
Drug: P03277 at 0.05 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
Trial: NCT04675996
Drug: INT-1B3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-min i.v. infusions twice per week in 21-day cycles
Trial: NCT00376896
Drug: GW876008 200mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW876008
Trial: NCT00376896
Drug: GW876008 20mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW876008 20mcg
Trial: NCT03832010
Drug: Hydrocortisone Ointment
RxNorm normalized name: Hydrocortisone Ointment
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
Trial: NCT02349295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03912259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution,~Route of administration: SC
Trial: NCT00007189
Drug: Naproxen Sodium (Aleve)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00007189
Drug: Celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00791024
Drug: CRC-Pharma 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT00440050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo capsules twice a day for 18 months
Trial: NCT02219087
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
Trial: NCT02709473
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
Trial: NCT00127075
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mcg, once a week
Trial: NCT00127075
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo treatments
Trial: NCT00191074
Drug: somatropin, rDNA origin, for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255086
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg placebo pill
Trial: NCT00434122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day.
Trial: NCT02170987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00717990
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Trial: NCT04480294
Drug: HRS5091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose in group 1-5~Multiple doses in group 6-9
Trial: NCT01963208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01892319
Drug: other injectable antidiabetic treatment regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician
Trial: NCT03403725
Drug: MEN1309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEN1309 solution for intravenous infusion once every 3 weeks
Trial: NCT02523820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
Trial: NCT02207595
Drug: UCB5857
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use
Trial: NCT04191577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00332800
Drug: Nutritional Supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02559206
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT02755844
Drug: metronomic cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
Trial: NCT04193852
Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablets
Trial: NCT04193852
Drug: Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated Tablets
Trial: NCT04447404
Drug: DUR-928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04447404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04205578
Drug: Normal Saline 0.9% Infusion Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
Trial: NCT02539342
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed
Trial: NCT02029352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composition, apart from the active substance, is otherwise identical to the investigational medical product.
Trial: NCT00111475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT01308723
Drug: RO5323441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalating doses iv
Trial: NCT01308723
Drug: RO5323441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 2 weeks
Trial: NCT01593163
Drug: Ibuprofen EchoG
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
Trial: NCT01593163
Drug: Standard ibuprofen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
Trial: NCT02501343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
Trial: NCT01816594
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
Trial: NCT01206478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
Trial: NCT01816594
Drug: BKM120 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
Trial: NCT01951430
Drug: Antibiotic and antifungal drugs
RxNorm normalized name: Antifungal Antibiotics, Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03905655
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of placebo tablets administered orally depends on the arm
Trial: NCT03446651
Drug: Lysine Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
Trial: NCT01516047
Drug: Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg to 2000 mg abiraterone acetate suspension on Day 1
Trial: NCT01516047
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg abiraterone acetate suspension on Day 1